We focus on phases II & III clinical trials.
Therapeutic areas are Alzheimer's Disease,
Epilepsy, Migraine Headaches, Multiple Sclerosis Diabetic Neuropathic
Pain and Stroke. Our investigators have successfully been conducting studies
with the following pharmaceutical companies:
Alzheimer’s
Disease
|
Sponsor
|
Drug Name
|
Phase |
Protocol
|
Enrollment
Commitment |
Completed
Patients |
|
Eli Lilly |
Olanzepine |
II |
FID-US-HGIC-008 |
10 |
8 |
|
Janssen |
Galantamine |
III |
GAl-USA 10-18 |
63 |
55 |
|
Neurochem |
Alzhemed |
III |
CL–758007 |
12 |
23 |
|
Novartis |
Exelon |
IIII |
CENA713BUS13 |
08 |
11 |
|
ONO |
N/A |
II |
ONO-2506 |
08 |
08 |
|
BAYER |
METRIFONATE |
IIII |
N/A |
08 |
06 |
|
PARKE-DAVIS |
MILAMELINE |
III |
N/A |
12 |
10 |
|
HOECHST |
MENTANE |
III |
N/A |
10 |
08 |
Migraine Headaches
|
Sponsor
|
Drug Name
|
Phase |
Protocol
|
Enrollment
Commitment |
Completed
Patients |
|
J&J PRI |
Topamax |
III |
MIG-002 |
08 |
15 |
|
AstraZeneca |
Zomig |
III |
311CUS/0022 |
10 |
12 |
|
GSK |
Sumatriptan |
III |
SUM40299 |
08 |
09 |
|
ZICAM |
MTX-M3 |
III |
MTX-M3 |
10 |
10 |
Epilepsy
|
Sponsor
|
Drug Name
|
Phase |
Protocol
|
Enrollment
Commitment |
Completed
Patients |
|
J&J PRI |
Topamax |
III |
EPMN-106 |
10 |
06 |
|
Élan |
Zonegran |
III |
AN46046-304 |
06 |
09 |
|
GSK |
Lamictal |
III |
LAM40124 |
06 |
03 |
Multiple
Sclerosis
|
Sponsor
|
Drug Name
|
Phase |
Protocol
|
Enrollment
Commitment |
Completed
Patients |
|
Teva |
Copaxone |
II |
Copolymer |
10 |
6 |
|
Peptimmune |
Cytokine |
II |
MS-001 |
20 |
24 |
Diabetic
Neuropathic Pain
|
Sponsor
|
Drug Name
|
Phase |
Protocol
|
Enrollment
Commitment |
Completed
Patients |
|
J&J PRD |
Topamax |
III |
NP-001 |
10 |
07 |
|
SANKYO |
Fidaristat |
II |
SNK-860-201 |
06 |
03 |
Stroke
|
Sponsor
|
Drug Name
|
Phase |
Protocol
|
Enrollment
Commitment |
Completed
Patients |
|
Park-Davis |
Fosphenytoin |
II |
N/A |
10 |
08 |
|
ONO |
ONO-2506 |
II |
ONO-2506 |
08 |
06 |
|
BMS |
|
II |
N/A |
10 |
07 |
|
Yamanuchi |
YM 872 |
II |
YM 872 |
06 |
04 |
Lower
Back Pain
|
Sponsor
|
Drug Name
|
Phase |
Protocol
|
Enrollment
Commitment |
Completed
Patients |
|
Praecis |
Latranal |
III |
2145-00-03 |
12 |
11 |
|
